-
公开(公告)号：US20090285803A1
公开(公告)日：2009-11-19
申请号：US12465169
申请日：2009-05-13
申请人： Jasvinder Atwal , Marc Tessier-Lavigne , Yan Wu
发明人： Jasvinder Atwal , Marc Tessier-Lavigne , Yan Wu
IPC分类号： A61K39/395 , C07K16/00 , C12N15/13 , C12N15/85 , C12N1/00 , C12N5/16 , C12P21/02 , C07K16/42 , A61P25/28
CPC分类号： C07K16/2803 , C07K2317/56 , C07K2317/76
摘要： The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified.
摘要翻译： 本发明一般涉及神经发育和神经障碍。 本发明具体涉及鉴定髓鞘相关抑制系统的新型调节剂以及所鉴定的调节剂的各种用途。
-
公开(公告)号：US20100047232A1
公开(公告)日：2010-02-25
申请号：US12208883
申请日：2008-09-11
CPC分类号： G01N33/5058 , G01N2500/02
摘要： The present invention provides methods and compositions related to CNS function and diseases.
摘要翻译： 本发明提供了与CNS功能和疾病有关的方法和组合物。
-
公开(公告)号：US20090232794A1
公开(公告)日：2009-09-17
申请号：US12316130
申请日：2008-12-09
IPC分类号： A61K39/395 , G01N33/566 , G01N33/567 , C07K16/00 , C07H21/02 , C12N5/06 , A61K31/7105
CPC分类号： G01N33/5058 , G01N33/5073 , G01N2333/525 , G01N2333/705 , G01N2500/00
摘要： The present invention provides methods and compositions related to CNS function and diseases.
摘要翻译： 本发明提供了与CNS功能和疾病有关的方法和组合物。
-
公开(公告)号：US20090169542A1
公开(公告)日：2009-07-02
申请号：US11983775
申请日：2007-11-09
IPC分类号： A61K39/395 , G01N33/53 , C12Q1/68 , C07K16/00 , C07K14/00 , C07H21/02 , C07H1/00 , A61K38/02 , A61K31/70 , A61K31/7088 , A61P25/00
CPC分类号： G01N33/5058 , G01N2500/02
摘要： The present invention provides methods and compositions related to CNS function and diseases.
-
公开(公告)号：US07943329B2
公开(公告)日：2011-05-17
申请号：US11983775
申请日：2007-11-09
IPC分类号： G01N33/567
CPC分类号： G01N33/5058 , G01N2500/02
摘要： The present invention provides methods and compositions related to CNS function and diseases.
摘要翻译： 本发明提供了与CNS功能和疾病有关的方法和组合物。
-
公开(公告)号：US08350010B2
公开(公告)日：2013-01-08
申请号：US13171289
申请日：2011-06-28
IPC分类号： C07K16/18
CPC分类号： A61K39/3955 , A61K45/06 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2842 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/74
摘要： The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
摘要翻译： 本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。 本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。 本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。
-
公开(公告)号：US20120195908A1
公开(公告)日：2012-08-02
申请号：US13171289
申请日：2011-06-28
IPC分类号： A61K39/395 , A61P7/00 , C12N9/96 , C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2842 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/74
摘要： The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
摘要翻译： 本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。 本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。 本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。
-
公开(公告)号：US20090220504A1
公开(公告)日：2009-09-03
申请号：US12293382
申请日：2007-03-21
IPC分类号： A61K39/395 , C07K16/28 , C07H21/00 , C12N15/63 , C12N5/00 , G01N33/53 , A61P35/00 , A61P37/00 , A61P27/02
CPC分类号： A61K39/3955 , A61K45/06 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2842 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/74
摘要： The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
摘要翻译： 本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。 本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。 本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。
-
公开(公告)号：US20110223630A1
公开(公告)日：2011-09-15
申请号：US12997297
申请日：2009-06-12
IPC分类号： C12Q1/02
CPC分类号： G01N33/5058 , G01N33/6896
摘要： Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue.
摘要翻译： 提出了筛选抑制神经变性的化合物的方法。 APP的脱落可能是神经变性的有用标志物，并且抑制APP脱落的化合物可用作神经退行性抑制剂。 这样的化合物可用于治疗和/或预防各种神经疾病，病症和神经元损伤，并且可以增强哺乳动物神经细胞或组织的生长，再生或存活。
-
10.发明申请公开(公告)号：US20100203044A1
公开(公告)日：2010-08-12
申请号：US12520044
申请日：2007-12-21
IPC分类号： A61K39/395 , C12N5/00 , A61K38/16 , A61P25/00 , G01N33/53 , C07K16/00 , C07K14/00 , G01N33/68
CPC分类号： C07K16/18 , A61K38/00 , C07K14/70578 , C07K16/2878 , C07K2317/76 , C07K2319/02 , C07K2319/30 , C07K2319/61 , C12N15/1138 , C12N2310/14
摘要： Methods and compositions comprising DR6 antagonists for use in treating neurological disorders, including Alzheimer's disease, are provided. The DR6 antagonists include anti-APP antibodies, anti-DR6 antibodies, DR6 immunoadhesins and DR6 variants (and fusion proteins thereof) which enhance growth, regeneration or survival of mammalian neuronal cells or tissue.
摘要翻译： 提供了包含用于治疗神经障碍（包括阿尔茨海默氏病）的DR6拮抗剂的方法和组合物。 DR6拮抗剂包括增强哺乳动物神经细胞或组织的生长，再生或存活的抗APP抗体，抗DR6抗体，DR6免疫粘附素和DR6变体（及其融合蛋白）。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.025 秒)
